Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sihai Shuyu Formula (SHSY)** is a traditional Chinese herbal formula, originally developed during the Qing Dynasty for gallbladder treatment and later adapted for therapeutic use in thyroid disorders, particularly Graves’ disease. It is composed of a combination of sargassum (Hai zao), thalluslaminariae (Kun bu), endoconcha sepiae (Hai piao xiao), goncha meretricis seu cyclinae (Ge ke), citrus reticulata (Chen Pi), and aucklandiae radix (Mu Xiang)[3][5]. The formula is traditionally indicated for moving Qi, resolving Phlegm, softening hardness, and dissolving masses[5]. Modern preclinical studies indicate promising potential for treating Graves’ disease by modulating the IGF1R/PI3K/Akt signaling pathway, reducing serum thyroxine (T4) and thyrotropin receptor antibody (TRAb) levels, and improving thyroid tissue morphology[1][3]. Key active components identified include Guggulsterone, Betulinic aldehyde, and Forsythoside H. SHSY is considered as an adjunctive therapy alongside conventional treatments such as antithyroid drugs, surgery, or radioiodine therapy. Currently, the evidence is based on animal studies; clinical data in humans are lacking[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sihai Shuyu Formula.